Medicines and Healthcare products Regulatory Agency
| 1: Authorisation Number | UK MIA(IMP) 19124 | 
|---|---|
| 2: Name of authorisation holder | CURIA (SCOTLAND) LIMITED | 
| 3: Address(es) of manufacturing site(s) | CURIA (SCOTLAND) LIMITED, BLOCK K, TODD CAMPUS, WEST OF SCOTLAND SCIENCE PARK, ACRE ROAD, GLASGOW, G20 0XA, UNITED KINGDOM | 
| 4: Legally registered address of authorisation holder | CURIA (SCOTLAND) LIMITED, TODD CAMPUS, WEST OF SCOTLAND SCIENCE PARK, GLASGOW, G20 0XA, UNITED KINGDOM | 
| 5: Scope of authorisation and dosage forms | ANNEX 1 and/ or ANNEX 2 | 
| 6: Legal Basis of authorisation | |
| 7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation | Confidential | 
| 8: Authorisation Date | 29/04/2025 | 
| 9: Annexes attached | Annex 1 and/or Annex 2 | 
SCOPE OF AUTHORISATION
        Annex 2
        
          Name and address of the site: 
          
      
              
          
  
        
        
        CURIA (SCOTLAND) LIMITED, BLOCK K, TODD CAMPUS, WEST OF SCOTLAND SCIENCE PARK, ACRE ROAD, GLASGOW, G20 0XA, UNITED KINGDOM
                                          Human Investigational Medicinal Products
                  
      | Authorised Operations | 
| MANUFACTURING OPERATIONS (according to part 1) | 
| Part 1 - MANUFACTURING OPERATIONS | 
| [ 1.1 ] Sterile Investigational Medicinal Products | 
| [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) | 
| [ 1.1.1.2 ] Lyophilisates | 
| [ 1.1.1.4 ] Small volume liquids | 
| [ 1.1.2 ] Terminally Sterilised (processing operations for the following dosage forms) | 
| [ 1.1.2.1 ] Large volume liquids | 
| [ 1.1.2.3 ] Small volume liquids | 
| [ 1.1.2.5 ] Other terminally sterilised prepared products Implant for Injection using Glide Technologies Solid Dose Injector System;; Drug loaded, lyphilised polymer beads for intra-arterial injection | 
| [ 1.2 ] Non-sterile investigational medicinal products | 
| [ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms) | 
| [ 1.2.1.5 ] Liquids for external use | 
| [ 1.2.1.6 ] Liquids for internal use | 
| [ 1.2.1.8 ] Other solid dosage forms | 
| [ 1.3 ] Biological investigational medicinal products | 
| [ 1.3.1 ] Biological medicinal products | 
| [ 1.3.1.5 ] Biotechnology products | 
| [ 1.3.1.6 ] Human or animal extracted products | 
| [ 1.3.1.8 ] Other biological medicinal products Proteins and Biologics derived from cell lines | 
| [ 1.4 ] Other investigational medicinal products or manufacturing activitiy | 
| [ 1.4.1 ] Manufacture of: | 
| [ 1.4.1.3 ] Other Hormones, Cytotoxics/Cytostatics, Non-Cytotoxic Organic/Inorganic Chemically active. | 
| [ 1.4.2 ] Sterilisation of active substances/excipients/finished products: | 
| [ 1.4.2.1 ] Filtration | 
| [ 1.4.2.2 ] Dry heat | 
| [ 1.4.2.3 ] Moist heat | 
| [ 1.5 ] Packaging | 
| [ 1.5.2 ] Secondary packaging | 
| [ 1.6 ] Quality control testing | 
| [ 1.6.1 ] Microbiological: sterility | 
| [ 1.6.2 ] Microbiological: non-sterility | 
| [ 1.6.3 ] Chemical/Physical | 
| [ 1.6.4 ] Biological | 
